The Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) developed by Luye Pharma Group on its proprietary transdermal patch platform is expected to launch in Spain in June this year. 

 
New Packaging for Rivastigmine MD

In 2021, Rivastigmine MD was approved for marketing in several European countries, including Spain, for the treatment of mild to moderate dementia associated with Alzheimer's disease. In September 2021, the Group entered into an agreement with Esteve Pharmaceuticals, S.A. (ESTEVE), granting the latter exclusive commercial rights to the product in Spain. According to the two companies’ business plan, the first batch of Rivastigmine MD will be delivered to ESTEVE within the next few weeks, with ESTEVE expected to launch the product in Spain in June this year. The product is an important strategic addition to ESTEVE’s central nervous system (CNS) portfolio, building on its depth of knowledge in this therapeutic area.

“The collaboration with ESTEVE represents an important milestone in our commitment to addressing unmet needs for senior patients in Europe. By leveraging ESTEVE’s extensive CNS experience and strong business operating system, we believe we will soon be able to bring this new therapy to patients in Europe,” said Bruno Delie, General Manager of Luye Switzerland. “We aim to improve quality of life for people suffering from dementia, as well as for their families, friends and caregivers.”

Rivastigmine MD employs an innovative drug delivery system for Rivastigmine via twice-weekly transdermal administration. The product requires a lower application frequency than the once-daily Rivastigmine patches generally available in the market, enabling improvements to patients’ medication adherence. Due to its transdermal route of administration, Rivastigmine MD is convenient for patients with difficulty swallowing, potentially lowering the incidence of gastrointestinal adverse reactions such as nausea and vomiting when compared with the oral formulation. 

The Group is accelerating the development and commercialization of Rivastigmine MD in the global market. Outside of Europe, the Marketing Authorization Application (MAA) for the product has been accepted by China’s National Medical Products Association, and a Phase III clinical trial is currently underway in Japan.

About ESTEVE
ESTEVE (www.esteve.com) is an international pharmaceutical company with headquarters in Barcelona. Its mission is to advance in innovation to improve the lives of people and, since it was founded in 1929, it has focused on providing solutions for medical needs that are not yet covered. ESTEVE has a significant presence in Europe and the USA. The company operates in the US through subsidiaries and its own production facilities dedicated to the development and manufacture of active pharmaceutical ingredients in Spain, Mexico and China, as well as a pharmaceutical plant in Germany.